Maintenance and tolerability of infliximab in a cohort of 152 patients with rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 26, Issue 1, 2008, Pages 18-23

  Figueiredo, Isabelle Tavares ^a   Morel, Jacques ^a   Sany, Jacques ^a   Combe, Bernard ^a  

^a LAPEYRONIE HOSPITAL   (France)

Author keywords

Infliximab; Maintenance; Rheumatoid arthritis; Tolerance

Indexed keywords

ANTIHISTAMINIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD SALT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; STEROID;

ADULT; AGED; ALLERGY; ARTICLE; BREAST CARCINOMA; COHORT ANALYSIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLOW UP; HUMAN; INFECTION; INFECTION RATE; LABORATORY TEST; LONG TERM CARE; LUNG NODULE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN INFECTION; SMOKING; THORAX PAIN; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED;

EID: 40749125715     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. MAINI RN, BREEDVELD FC, KALDEN JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63.
2. MAINI R, ST CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
3. MAINI RN, BREEDVELD FC, KALDEN JR et al.: Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004; 50: 1051-65.
4. LIPSKY PE, VAN DER HEIJDE DM, ST CLAIR LW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-602.
5. ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344: 1125-7.
6. ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10.
7. BREEDVELD FC, EMERY P, KEYSTONE E et al.: Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004; 63: 149-55.
8. ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36: 1681-90.
9. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
10. PREVOO ML, VAN'T HOF MA, KUPER HH, VAN LEEUWEN MA, VAN DE PUTTE LB, VAN RIEL PL: Modified disease activity scores that include twenty-eight-joint Counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
11. WOLFE F, MICHAUD K, DEWITT EM: Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: Methodological and interpretive issues. Ann Rheum Dis 2004; 63 (Suppl. 2): Ii13-ii17.
12. GEBOREK P, CRNKIC M, PETERSSON IF, SAXNE T: Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: Clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002; 61: 793-8.
13. FLENDRIE M, CREEMERS MC, WELSING PM, DEN BROEDER AA, VAN RIEL PL: Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003; 62 (Suppl. 2): Ii30-3.
14. STERN R, WOLFE F: Infliximab doRe and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol 2004; 31: 1538-45.
15. FINCKH A, SIMARD JF, GABAY C, GUERNE PA: Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006; 65: 746-52.
16. EDREES AF, MISRA SN, ABDOU NI: Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: Correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin Exp Rheumatol 2005; 23: 469-74.
17. ALBANO SA, SANTANA-SAHAGUN E, WEISMAN MH: Cigarette smoking and rheumatoid arthritis. Semin Arthritis Rheum 2001; 31: 146-59.
18. MANFREDSDOTTIR VF, VIKINGSDOTTIR T, JONSSON T et al.: The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 2006; 45: 734-40.
19. CRISWELL LA, SAAG KG, MIKULS TR et al.: Smoking interacts with genetic risk factors in the development of rheumatoid arthritis among older Caucasian women. Ann Rheum Dis 2006; 65: 1163-7.
20. PEDERSEN M, JACOBSEN S, KLARLUND M et al.: Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res Ther 2006; 8: R133.
21. FURST DE, BREEDVELD FC, KALDEN JR et al.: Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNF-alpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis 2004; 63 (Suppl. 2): Ii2-ii12
22. BOCK NN, METZGER BS, TAPIA JR, BLUMBERG HM: A tuberculin screening and isoniazid preventive therapy program in an inner-city population. Am J Respir Crit Care Med 1999; 159: 295-300.
23. CARMONAL, GOMEZ-REINO JJ, RODRIGUEZ-VALVERDE V et al.: Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52: 1766-72.
24. GEBOREK P, BLADSTROM A, TURESSON C et al.: Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005; 64: 699-703.
25. ASKLING J, FORED CM, BAECKLUND E et al.: Haematopoietic malignancies in rheumatoid arthritis: Lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1414-20.
26. ASKLING J, FORED CM, BRANDT L et al.: Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1421-6.